How Sinha was paid
$544,400 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Incentive | Other | Total |
|---|---|---|---|---|---|
| Diana BrainardAlloVir’s Former Chief Executive Officer | $610,638 | — | — | $2,418,031 | $3,028,669 |
| Vikas SinhaAlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | $375,448 | — | $168,952 | — | $544,400 |
| Edward MillerAlloVir’s Former General Counsel and Secretary | $451,352 | — | $180,541 | $13,800 | $645,693 |
| Brett HagenAlloVir’s Former Chief Accounting Officer and our Current Chief Accounting Officer | $385,320 | $397,191 | — | $13,800 | $796,311 |
What changed and why
- $2.4M$2,418,031 in all other compensation for Brainard primarily reflected $2,357,632 in severance payments.
- $397K$397,191 retention bonuses were paid to Hagen under February and May 2024 retention agreements.
- $169K$168,952 was reported as Sinha’s 2024 non-equity incentive compensation.
- $181K$180,541 was reported as Miller’s 2024 non-equity incentive compensation.
- 60%60%, 45%, 40% and 35% were the 2024 target bonus percentages for Brainard, Sinha, Miller and Hagen.
- 2024 equity awards were reported as zero for every named executive officer.
Other Kalaris Therapeutics proxy statements
- 2026 proxy statement
Andrew Oxtoby paid $2.6M (+31% on the year).
Filed Apr 24, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.